Enantiomers of lead compounds for neurodegenerative diseases has been granted in the U.S.A.
Avidin’s patent, entitled ‘Enantiomers of 8-Hydroxy Quinoline derivatives and the synthesis’ was granted by the US Patent Office under publication number US 2017/0197936 A1 on May, 14 2019. Granting our patent in the US was very important to the company, as protection of this IP related to our clinical candidate against Alheimer’s disease is crucial for our clinical development program, as well as in attracting potential VCs” – said László Puskás, CEO.
Summary: The novel medicinal and/or pharmaceutical compositions empowers these enantiomers to be used preferably as cytoprotective, neuroprotective, cardioprotective, anxiolytic and antidepressant agents for the treatment of neuropsychiatric and neurologic diseases and diseases in connections with transplantations and with ischemia and reperfusion injuries, further the inhibition of organ and skin graft rejection. According to our studies the R-enantiomer has either sole or high biological effect.